Efficacy and safety of desloratadine and phenylephrine for the control of symptoms associated with allergic rhinitis: A systematic review with meta-analysis

Aim: Allergic rhinitis (AR) is a disease with genetic, immunological, and inflammatory component, several therapeutic options are available. We conduct a systematic review to evaluate desloratadine and phenylephrine efficacy to control RA associated symptoms. Methods: 43 studies were included: 24 parallel-arm, 5 cross-over, one blinded, double-dummy, 7 cross-blinded, double-dummy, and 6 unblinded open-label trials. 22% were conducted in subjects with perennial allergic rhinitis, 78% were in subjects with predominantly seasonal behavior. The studies provide 6,772 subjects who underwent desloratadine, and 6,456 who received placebo or active drug. Results: A significant impact of the administration of desloratadine on TSS [week 2, MD –1.26 (95% CI -2.28 to -0.25h)] TNSS [week 2 MD –0.73 (95% CI -0.93 to -0.53)]; TNNSS [week 2 MD -0.51 (95% CI -0.72 to -0.29)]; RNCS [week 2 MD -0.16 (95% CI -0.17 to 0.50)], rhinorrhea [week 2, MD –0.28 (95% CI -0.48 to -0.07)]; nasal congestion [week 2 MD –0.25 (95% CI -0.45 to -0.06)]; quality of life [week 2, MD –0.29 (95% CI -0.42 to -0.17)]; peak nasal flow [week 2 MD 1.76 (95% CI 0.04 to 3.57)], and other parameters was identified. The impact was significant not only when compared with a placebo, but also when compared with several active ingredients of control drugs. Conclusion: Desloratadine, as well as phenylephrine are safe and effective for the control of total, nasal and non-nasal symptoms associated with allergic rhinitis, effect associated with modulation of inflammation and immunomodulatory cascades, its use in combination is an excellent therapeutic option.